GT Biopharma Past Earnings Performance
Past criteria checks 0/6
GT Biopharma has been growing earnings at an average annual rate of 55.4%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
55.4%
Earnings growth rate
83.8%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | n/a |
Return on equity | -101.6% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How GT Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -8 | 7 | 6 |
30 Sep 23 | 0 | -10 | 8 | 8 |
30 Jun 23 | 0 | -15 | 11 | 9 |
31 Mar 23 | 0 | -16 | 11 | 8 |
31 Dec 22 | 0 | -21 | 12 | 9 |
30 Sep 22 | 0 | -33 | 21 | 12 |
30 Jun 22 | 0 | -32 | 22 | 11 |
31 Mar 22 | 0 | -34 | 24 | 10 |
31 Dec 21 | 0 | -58 | 48 | 10 |
30 Sep 21 | 0 | -46 | 38 | 4 |
30 Jun 21 | 0 | -44 | 35 | 2 |
31 Mar 21 | 0 | -56 | 33 | 2 |
31 Dec 20 | 0 | -28 | 6 | 0 |
30 Sep 20 | 0 | -23 | 5 | 0 |
30 Jun 20 | 0 | -50 | 7 | 1 |
31 Mar 20 | 0 | -36 | 7 | 1 |
31 Dec 19 | 0 | -39 | 10 | 2 |
30 Sep 19 | 0 | -41 | 11 | 3 |
30 Jun 19 | 0 | -247 | 12 | 3 |
31 Mar 19 | 0 | -254 | 12 | 6 |
31 Dec 18 | 0 | -259 | 12 | 9 |
30 Sep 18 | 0 | -261 | 16 | 8 |
30 Jun 18 | 0 | -156 | 138 | 7 |
31 Mar 18 | 0 | -149 | 137 | 4 |
31 Dec 17 | 0 | -144 | 135 | 1 |
30 Sep 17 | 0 | -141 | 129 | 1 |
30 Jun 17 | 0 | -14 | 5 | 1 |
31 Mar 17 | 0 | -10 | 6 | 1 |
31 Dec 16 | 0 | 10 | 8 | 1 |
30 Sep 16 | 0 | -14 | 10 | 1 |
30 Jun 16 | 0 | -12 | 10 | 1 |
31 Mar 16 | 0 | 14 | 10 | 1 |
31 Dec 15 | 0 | -21 | 8 | 1 |
30 Sep 15 | 0 | -14 | 7 | 0 |
30 Jun 15 | 0 | -17 | 5 | 0 |
31 Mar 15 | 0 | -44 | 4 | 0 |
31 Dec 14 | 0 | -23 | 2 | 0 |
30 Sep 14 | 0 | -5 | 1 | 0 |
30 Jun 14 | 0 | -1 | 1 | 0 |
31 Mar 14 | 0 | -1 | 1 | 0 |
31 Dec 13 | 0 | -1 | 1 | 0 |
30 Sep 13 | 1 | -1 | 2 | 0 |
30 Jun 13 | 0 | -2 | 3 | 0 |
Quality Earnings: OXIA is currently unprofitable.
Growing Profit Margin: OXIA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OXIA is unprofitable, but has reduced losses over the past 5 years at a rate of 55.4% per year.
Accelerating Growth: Unable to compare OXIA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OXIA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: OXIA has a negative Return on Equity (-101.62%), as it is currently unprofitable.